Toxic interaction between risperidone and clozapine: A case report

Although atypical antipsychotics have generally a decreased risk of neurotoxicity, there are reports regarding various neurotoxic or idiosyncratic reactions including neuroleptic malignant syndrome (NMS). The authors present here the toxic interaction between risperidone (RIS) and clozapine (CLZ) in...

Full description

Saved in:
Bibliographic Details
Published in:Progress in neuro-psychopharmacology & biological psychiatry 2002-02, Vol.26 (2), p.407-409
Main Authors: Kontaxakis, Vassilis P., Havaki-Kontaxaki, Beata J., Stamouli, Sophia S., Christodoulou, George N.
Format: Article
Language:English
Subjects:
Adult
Antipsychotic Agents - adverse effects
Antipsychotic Agents - pharmacology
Biological and medical sciences
Clozapine
Clozapine - adverse effects
Clozapine - pharmacology
Diagnosis, Differential
Drug Interactions
Drug toxicity and drugs side effects treatment
Humans
Male
Medical sciences
Neuroleptic malignant syndrome
Neuroleptic Malignant Syndrome - blood
Neuroleptic Malignant Syndrome - diagnosis
Neurotoxicity
Neurotoxicity Syndromes - blood
Neurotoxicity Syndromes - diagnosis
Pharmacology. Drug treatments
Risperidone
Risperidone - adverse effects
Risperidone - pharmacology
Schizophrenia - blood
Schizophrenia - drug therapy
Toxicity: nervous system and muscle
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Although atypical antipsychotics have generally a decreased risk of neurotoxicity, there are reports regarding various neurotoxic or idiosyncratic reactions including neuroleptic malignant syndrome (NMS). The authors present here the toxic interaction between risperidone (RIS) and clozapine (CLZ) in a first-episode schizophrenic patient. A 20-year-old man suffering from first-episode schizophrenia—catatonic subtype, developed a neurotoxic syndrome, which has been characterized as a mild form of NMS, after CLZ (100 mg/day) was added to a regimen of RIS (16 mg/day). The NMS symptomatology subsided only by drug discontinuation and supportive care. Later, CLZ monotherapy restarted without further complications. This case report shows that neurotoxic syndromes, even NMS, may occur during combination therapy with RIS and CLZ.
ISSN:0278-5846
1878-4216
DOI:10.1016/S0278-5846(01)00257-3